

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CIDECA in direct ELISAs and Western blots. In direct ELISAs, less than 3% cross-reactivity with recombinant human CIDECA is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human CIDECA Met75-His176 Accession # Q96AQ7
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

CIDE-3 (Cell death-Inducing DNA fragmentation factor-α-like Effector protein 3; also CIDECA and FSP27 in mouse) is a 24-32 kDa member of the CIDE family of molecules. It is a lipid droplet stabilizer that is expressed in hepatocytes and adipocytes, and found to be associated with both mitochondria and the surface of cytoplasmic lipid droplets. CIDE-3 is unstable in the absence of triglycerides and free fatty acids, and is subject to ubiquitin-mediated degradation. In the presence of elevated fatty acids or triglycerides, CIDE-3 half-life is prolonged, and it assists in the formation of lipid droplets. Although other CIDE family members are associated with the initiation of apoptosis, it is unclear if CIDE-3 possesses such activity. Human CIDE-3 is 238 amino acids (aa) in length, and contains one CIDE domain (aa 41-120). There are multiple isoform variants. Two possess alternative start sites, one at Met74, and another 14 aa upstream of the standard site. A third isoform shows an insertion of ten aa after Lys69, while a fourth isoform possesses a 60 aa substitution for aa 70-238. Over aa 75-176, human CIDE-3 shares 84% aa identity with mouse CIDE-3.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.